Your browser doesn't support javascript.
loading
Interleukin-17A (IL-17A): A silent amplifier of COVID-19.
Maione, Francesco; Casillo, Gian Marco; Raucci, Federica; Salvatore, Cristian; Ambrosini, Giovanna; Costa, Luisa; Scarpa, Raffaele; Caso, Francesco; Bucci, Mariarosaria.
Afiliação
  • Maione F; Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy.
  • Casillo GM; Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy.
  • Raucci F; Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy.
  • Salvatore C; New.Fa.DEm SRL, Viale Ferrovie Dello Stato, 1, 80014 Giugliano in Campania, Naples, Italy.
  • Ambrosini G; New.Fa.DEm SRL, Viale Ferrovie Dello Stato, 1, 80014 Giugliano in Campania, Naples, Italy.
  • Costa L; Department of Clinical Medicine and Surgery, School of Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini, 5, 80131 Naples, Italy.
  • Scarpa R; Department of Clinical Medicine and Surgery, School of Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini, 5, 80131 Naples, Italy.
  • Caso F; Department of Clinical Medicine and Surgery, School of Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini, 5, 80131 Naples, Italy. Electronic address: francesco.caso@unina.it.
  • Bucci M; Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy. Electronic address: mrbucci@unina.it.
Biomed Pharmacother ; 142: 111980, 2021 Oct.
Article em En | MEDLINE | ID: mdl-34364043
One of the hallmarks of COVID-19 is the cytokine storm that provokes primarily pneumonia followed by systemic inflammation. Emerging evidence has identified a potential link between elevated interleukin-17A (IL-17A) levels and disease severity and progression. Considering that per se, IL-17A can activate several inflammatory pathways, it is plausible to hypothesize an involvement of this cytokine in COVID-19 clinical outcomes. Thus, IL-17A could represent a marker of disease progression and/or a target to develop therapeutic strategies. This hypothesis paper aims to propose this "unique" cytokine as a silent amplifier of the COVID-19 immune response and (potentially) related therapy.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Interleucina-17 / Síndrome da Liberação de Citocina / COVID-19 / Tratamento Farmacológico da COVID-19 Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Interleucina-17 / Síndrome da Liberação de Citocina / COVID-19 / Tratamento Farmacológico da COVID-19 Idioma: En Ano de publicação: 2021 Tipo de documento: Article